Literature DB >> 25302231

Isoniazid Induced Cutaneous Leukocytoclastic Vasculitis in Extra Pulmonary Tuberculosis (Pott's Spine): A Case Report.

Sowmya Bondalapati1, Dharma Rao V2, Dilip Rampure3, Rama Rao S2.   

Abstract

Anti-tuberculosis drugs frequently result in cutaneous adverse reactions but Isoniazid is known to have least toxic potential for cutaneous reactions. We report a rare case of Isoniazid induced cutaneous leucocytoclastic vasculitis. A 64-year-old male was diagnosed to have Pott's spine with multiple vertebral body involvement (D8-12 vertebrae). Subsequently, he was treated with first line anti-TB drugs i.e., Isoniazid, Rifampicin, Pyrazinamide and Ethambutol. On the fourth day of treatment with Anti Tuberculosis Treatment (ATT), the patient developed an erythematosus rash over right upper limb not associated with itching or pain, non-blanchable macules and papules over bilateral shins on lower limbs, petechiae on both forearms and hyper pigmented, scaly rash over right axilla and buttocks. The skin biopsy report was consistent with cutaneous leukocytoclastic vasculitis. Although rare, Isoniazid among anti-tuberculosis drugs should be considered as potential cause of drug-induced cutaneous leukocytoclastic vasculitis in the differential diagnosis of erythematosus rash with petechiae.

Entities:  

Keywords:  Anti tuberculosis drugs; Isoniazid; Leucocytoclastic vasculitis; Pott’s spine

Year:  2014        PMID: 25302231      PMCID: PMC4190753          DOI: 10.7860/JCDR/2014/9000.4688

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

1.  Cutaneous vasculitis associated with tuberculosis and its treatment.

Authors:  C H Chan; Y W Chong; A J Sun; G B Hoheisel
Journal:  Tubercle       Date:  1990-12

2.  Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.

Authors:  T Schaberg; K Rebhan; H Lode
Journal:  Eur Respir J       Date:  1996-10       Impact factor: 16.671

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 4.  Small-vessel vasculitis.

Authors:  J C Jennette; R J Falk
Journal:  N Engl J Med       Date:  1997-11-20       Impact factor: 91.245

5.  Cutaneous leukocytoclastic vasculitis accompanied by pulmonary tuberculosis.

Authors:  Maurício Carvalho; Robson Luiz Dominoni; Denise Senchechen; Artur Furlaneto Fernandes; Ismael Paulo Burigo; Eloisa Doubrawa
Journal:  J Bras Pneumol       Date:  2008-09       Impact factor: 2.624

6.  Cutaneous leukocytoclastic vasculitis due to anti-tuberculosis medications, rifampin and pyrazinamide.

Authors:  Joo-Hee Kim; Jun-Il Moon; Jeong Eun Kim; Gil-Soon Choi; Hae-Sim Park; Young-Min Ye; Hyunee Yim
Journal:  Allergy Asthma Immunol Res       Date:  2009-12-30       Impact factor: 5.764

7.  Circulating immune complexes in tuberculosis.

Authors:  N M Johnson; M W McNicol; E J Burton-Kee; J F Mowbray
Journal:  Thorax       Date:  1981-08       Impact factor: 9.139

8.  Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs.

Authors:  W C Tan; C K Ong; S C Lo Kang; M Abdul Razak
Journal:  Med J Malaysia       Date:  2007-06

Review 9.  Cutaneous tuberculosis: diagnosis and treatment.

Authors:  Joseph Barbagallo; Patricia Tager; Rosemary Ingleton; Ranella J Hirsch; Jeffrey M Weinberg
Journal:  Am J Clin Dermatol       Date:  2002       Impact factor: 7.403

  9 in total
  2 in total

Review 1.  Ceftriaxone-induced leukocytoclastic vasculitis: a case report and literature review of antibiotic-induced leukocytoclastic vasculitis.

Authors:  Aseel A Almasoudi; Eman S Bablghaith; Samaher I Alaauldeen; Ayman M Falemban; Ahlam A Sherbeeni; Adeeb A Bulkhi
Journal:  J Int Med Res       Date:  2022-05       Impact factor: 1.573

Review 2.  The coexistence of IgA vasculitis and tuberculosis: a case-based review.

Authors:  Reşit Yıldırım; Döndü Üsküdar Cansu; Burcu Ceren Ekti Uludoğan; Mustafa Dinler; Emel Tekin; Cengiz Korkmaz
Journal:  Rheumatol Int       Date:  2021-06-16       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.